On 15 August 2022, the Editorial Office was very honored to interview Prof. Jacqueline Cloos, a full professor in the Department of Hematology at Cancer Center Amsterdam, Netherlands.
Prof. Cloos contributed a high-quality paper “Characteristics of leukemic stem cells in acute leukemia and potential targeted therapies for their specific eradication” in May 2022. Based on this, the Editorial Office invited Prof. Cloos to share her team’s latest research in the field of leukemia. She mainly talked about the Minimal Residual Disease (MRD) in acute myeloid leukemia (AML) and some challenges they face during the research. At the end of the interview, Prof. Cloos concluded by sharing the current research hotspots and her cutting-edge perspective on AML.
Details of the interview
Q1. We learned that you have been working on acute leukemia for a long time. What motivates you to keep working on this? Could you please share something about your team’s recent research progress?
Q2. We know that one of your research projects is MRD in AML. What do you think are the challenges you face during the research?
Q3. Now you are dedicated to the therapy of acute leukemia in different age groups. Which age group do you find the most challenging to treat?
Q4. You mentioned in the article that “Despite many different surfaces and other markers being promising targets in eradicating Leukemic Stem Cells (LSCs), there are some important considerations that need to be taken into account before applying anti-LSC therapeutics ”, and you elaborated on some limitations in the article. Do you have any suggestions to reduce the limitations when implementing this therapeutic strategy?
Q5. Could you please talk about the current research hotspots and the prospects in the field of acute leukemia?
Introduction of Prof. Jacqueline Cloos
Prof. Jacqueline Cloos is a full professor in the Department of Hematology at Cancer Center Amsterdam. Prof. Cloos chairs the Dutch Acute Myeloid Leukemia (AML) Minimal Residual Disease (MRD) Working Party and is a member of the European LeukemiaNet AML MRD Working Party as coordinator of the flow cytometry group. She is the principal investigator in a variety of study areas within acute leukemia. Her research group is dedicated to targeting minimal residual disease to reduce the risk of relapse in patients with AML, and she also studies drug resistance against standard chemotherapy. Her projects include the investigation of novel treatment strategies such as splicing modulation and proteasome inhibition.
Respectfully Submitted by the Journal Editorial Office
Cancer Drug Resistance